Evidence map›Paper›PMID 36781685›Full record

ArticleNeurochemical research2023

Anti-inflammatory Action of BT75, a Novel RARα Agonist, in Cultured Microglia and in an Experimental Mouse Model of Alzheimer's Disease.

Xiuli Zhang, Shivakumar Subbanna, Colin R O Williams, Stefanie Canals-Baker, John F Smiley, Donald A Wilson, Bhaskar C Das, Mariko Saito

Open access · greenAbstract read
In one paragraph

Article in Neurochemical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Xiuli ZhangDivision of Neurochemistry, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.
Shivakumar SubbannaDivision of Neurochemistry, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.
Colin R O WilliamsEmotional Brain Institute, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA.
Stefanie Canals-BakerDivision of Neurochemistry, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.
John F SmileyDivision of Neurochemistry, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA.
Donald A WilsonEmotional Brain Institute, Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA.
Bhaskar C DasArnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 75 DeKalb Ave., Brooklyn, NY, 11201, USA. Bhaskar.Das@liu.edu.
Mariko SaitoDivision of Neurochemistry, Nathan Kline Institute for Psychiatric Research, 140 Old Orangeburg Rd, Orangeburg, NY, 10962, USA. mariko.saito@nki.rfmh.org.
Nathan Kline Institute for Psychiatric Research · USLong Island University · USNew York University · US

Funding

Long-lasting consequences of early ethanol on network activity during sleepR01AA023181 · NIAAA · NATHAN S. KLINE INSTITUTE FOR PSYCH RES · PI SAITO, MARIKO, SMILEY, JOHN F · 2014 to 2024
$3.6M
Receptor Specific Retinoids Probes to Study the Brain Damage Caused byDevelopmental Alcohol ExposureR21AA027374 · NIAAA · LONG ISLAND UNIVERSITY BROOKLYN CAMPUS · PI DAS, BHASKAR CHANDRA, SAITO, MARIKO · 2019 to 2020
$675k
NIAAA NIH HHS R01 AA023181NIAAA NIH HHS R01AA023181NIAAA NIH HHS R21 AA027374NIAAA NIH HHS R21AA027374
6 · The paper itself

Abstract

BT75, a boron-containing retinoid, is a novel retinoic acid receptor (RAR)α agonist synthesized by our group. Previous studies indicated that activation of retinoic acid (RA) signaling may attenuate progression of Alzheimer's disease (AD). Presently, we aimed to examine the anti-inflammatory effect of BT75 and explore the possible mechanism using cultured cells and an AD mouse model. Pretreatment with BT75 (1-25 µM) suppressed the release of nitric oxide (NO) and IL-1β in the culture medium of mouse microglial SIM-A9 cells activated by LPS. BMS195614, an RARα antagonist, partially blocked the inhibition of NO production by BT75. Moreover, BT75 attenuated phospho-Akt and phospho-NF-κB p65 expression augmented by LPS. In addition, BT75 elevated arginase 1, IL-10, and CD206, and inhibited inducible nitric oxide synthase (iNOS) and IL-6 formation in LPS-treated SIM-A9 cells, suggesting the promotion of M1-M2 microglial phenotypic polarization. C57BL/6 mice were injected intracerebroventricularly (icv) with streptozotocin (STZ) (3 mg/kg) to provide an AD-like mouse model. BT75 (5 mg/kg) or the vehicle was intraperitoneally (ip) injected to icv-STZ mice once a day for 3 weeks. Immunohistochemical analyses indicated that GFAP-positive cells and rod or amoeboid-like Iba1-positive cells, which increased in the hippocampal fimbria of icv-STZ mice, were reduced by BT75 treatment. Western blot results showed that BT75 decreased levels of neuronal nitric oxide synthase (nNOS), GFAP, and phosphorylated Tau, and increased levels of synaptophysin in the hippocampus of icv-STZ mice. BT75 may attenuate neuroinflammation by affecting the Akt/NF-κB pathway and microglial M1-M2 polarization in LPS-stimulated SIM-A9 cells. BT75 also reduced AD-like pathology including glial activation in the icv-STZ mice. Thus, BT75 may be a promising anti-inflammatory and neuroprotective agent worthy of further AD studies.

Indexed as

Alzheimer DiseaseMicrogliaAnimalsAnti-Inflammatory AgentsLipopolysaccharidesMiceMice, Inbred C57BLNF-kappa BProto-Oncogene Proteins c-aktAnti-Inflammatory AgentsLipopolysaccharidesNF-kappa BProto-Oncogene Proteins c-aktBoron-containing retinoidMicroglial polarizationNeurodegenerative diseaseNeuroinflammationNitric oxideRetinoic acid receptor

Identifiers

PMID36781685
PMCPMC10355192
OpenAlexW4320556438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.